elminda is the developer of Brain Network Analytics (BNA), an electrophysiology-based functional brain mapping, imaging, and monitoring technology. The company combines big data analytics, artificial intelligence, and brain network activation mapping to quantify function and dysfunction, disease progression, and therapeutic effects in cases of brain injuries such as concussion and other neurological and psychiatric disorders, including pain and depression. elminda's BNA system can help provide a universal screening for mental health and substance use problems in primary and specialty healthcare settings as a result of the COVID-19 crisis. In addition, the insights gained from the BNA test can allow better monitoring of the disease and enable personalized treatment plans. elminda's BNA technology has been CE marked and cleared by the FDA and is available for commercial and clinical use in the United States, Europe, Canada, and Israel.